478 related articles for article (PubMed ID: 28189534)
1. Metronomic chemotherapy and immunotherapy in cancer treatment.
Chen YL; Chang MC; Cheng WF
Cancer Lett; 2017 Aug; 400():282-292. PubMed ID: 28189534
[TBL] [Abstract][Full Text] [Related]
2. Metronomic chemotherapy: A potent macerator of cancer by inducing angiogenesis suppression and antitumor immune activation.
Biziota E; Mavroeidis L; Hatzimichael E; Pappas P
Cancer Lett; 2017 Aug; 400():243-251. PubMed ID: 28017892
[TBL] [Abstract][Full Text] [Related]
3. The potential clinical promise of 'multimodality' metronomic chemotherapy revealed by preclinical studies of metastatic disease.
Kerbel RS; Shaked Y
Cancer Lett; 2017 Aug; 400():293-304. PubMed ID: 28202353
[TBL] [Abstract][Full Text] [Related]
4. Metronomic chemotherapy for advanced breast cancer patients.
Cazzaniga ME; Dionisio MR; Riva F
Cancer Lett; 2017 Aug; 400():252-258. PubMed ID: 28017894
[TBL] [Abstract][Full Text] [Related]
5. Metronomic chemotherapy and nanocarrier platforms.
Abu Lila AS; Ishida T
Cancer Lett; 2017 Aug; 400():232-242. PubMed ID: 27838415
[TBL] [Abstract][Full Text] [Related]
6. Immunomodulatory effects of low dose chemotherapy and perspectives of its combination with immunotherapy.
Nars MS; Kaneno R
Int J Cancer; 2013 Jun; 132(11):2471-8. PubMed ID: 22927096
[TBL] [Abstract][Full Text] [Related]
7. Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer.
Kamat AA; Kim TJ; Landen CN; Lu C; Han LY; Lin YG; Merritt WM; Thaker PH; Gershenson DM; Bischoff FZ; Heymach JV; Jaffe RB; Coleman RL; Sood AK
Cancer Res; 2007 Jan; 67(1):281-8. PubMed ID: 17210709
[TBL] [Abstract][Full Text] [Related]
8. Metronomic chemotherapy for cancer treatment: a decade of clinical studies.
Romiti A; Cox MC; Sarcina I; Di Rocco R; D'Antonio C; Barucca V; Marchetti P
Cancer Chemother Pharmacol; 2013 Jul; 72(1):13-33. PubMed ID: 23475105
[TBL] [Abstract][Full Text] [Related]
9. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.
Pietras K; Hanahan D
J Clin Oncol; 2005 Feb; 23(5):939-52. PubMed ID: 15557593
[TBL] [Abstract][Full Text] [Related]
10. ATP-binding cassette transporters in tumor endothelial cells and resistance to metronomic chemotherapy.
Hida K; Kikuchi H; Maishi N; Hida Y
Cancer Lett; 2017 Aug; 400():305-310. PubMed ID: 28216371
[TBL] [Abstract][Full Text] [Related]
11. Metronomic chemotherapy from rationale to clinical studies: a dream or reality?
Gnoni A; Silvestris N; Licchetta A; Santini D; Scartozzi M; Ria R; Pisconti S; Petrelli F; Vacca A; Lorusso V
Crit Rev Oncol Hematol; 2015 Jul; 95(1):46-61. PubMed ID: 25656744
[TBL] [Abstract][Full Text] [Related]
12. A Decade of Experience in Developing Preclinical Models of Advanced- or Early-Stage Spontaneous Metastasis to Study Antiangiogenic Drugs, Metronomic Chemotherapy, and the Tumor Microenvironment.
Kerbel RS
Cancer J; 2015; 21(4):274-83. PubMed ID: 26222079
[TBL] [Abstract][Full Text] [Related]
13. Resistance to metronomic chemotherapy and ways to overcome it.
Riesco-Martinez M; Parra K; Saluja R; Francia G; Emmenegger U
Cancer Lett; 2017 Aug; 400():311-318. PubMed ID: 28259819
[TBL] [Abstract][Full Text] [Related]
14. Metronomic therapy: chemotherapy revisited.
Noronha V; Krishna MV; Patil V; Joshi A; Banavali SD; Prabhash K
Indian J Cancer; 2013; 50(2):142-8. PubMed ID: 23979206
[TBL] [Abstract][Full Text] [Related]
15. Metronomic chemotherapy: an attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance.
Kareva I; Waxman DJ; Lakka Klement G
Cancer Lett; 2015 Mar; 358(2):100-106. PubMed ID: 25541061
[TBL] [Abstract][Full Text] [Related]
16. Metronomic chemotherapy in metastatic colorectal cancer.
Woo IS; Jung YH
Cancer Lett; 2017 Aug; 400():319-324. PubMed ID: 28274890
[TBL] [Abstract][Full Text] [Related]
17. Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy.
Drevs J; Fakler J; Eisele S; Medinger M; Bing G; Esser N; Marmé D; Unger C
Anticancer Res; 2004; 24(3a):1759-63. PubMed ID: 15274352
[TBL] [Abstract][Full Text] [Related]
18. A Combination of Immune Checkpoint Inhibition with Metronomic Chemotherapy as a Way of Targeting Therapy-Resistant Cancer Cells.
Kareva I
Int J Mol Sci; 2017 Oct; 18(10):. PubMed ID: 29027915
[TBL] [Abstract][Full Text] [Related]
19. Metronomic chemotherapy: Back to the future!
André N; Padovani L; Verschuur A
Drug News Perspect; 2010 Mar; 23(2):143-51. PubMed ID: 20369080
[TBL] [Abstract][Full Text] [Related]
20. The use of nanoparticulate delivery systems in metronomic chemotherapy.
Yu DH; Ban FQ; Zhao M; Lu Q; Lovell JF; Bai F; Wang C; Guan YY; Luan X; Liu YR; Fang C; Chen HZ
Biomaterials; 2013 May; 34(16):3925-3937. PubMed ID: 23465835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
